Navigation Links
AMERIGROUP Reaches Agreement in Principle to Settle Illinois Qui Tam Litigation

VIRGINIA BEACH, Va., July 22 /PRNewswire-FirstCall/ -- AMERIGROUP Corporation (NYSE: AGP) announced today that it has reached a comprehensive settlement agreement in principle that will conclude its civil qui tam litigation relating to certain marketing practices of the Company's former Illinois health plan. The agreement in principle is subject to the completion of definitive settlement documentation by the parties.

In 2007, the Court had entered a judgment against the Company and its Illinois subsidiary of approximately $334 million, plus the fees of the Relator's counsel. Under the terms of the proposed settlement, the Company will pay $225 million to the United States and the State of Illinois, plus approximately $9 million in legal fees, and will not admit any wrongdoing. Additionally, in connection with the settlement, the Company will enter into a Corporate Integrity Agreement with the Office of the Inspector General of the U.S. Department of Health and Human Services.

"We are concluding this litigation now to remove a source of significant legal and financial uncertainty for our organization. With this matter resolved, we can concentrate fully on the business at hand -- meeting the healthcare needs of our members and continuing to serve our government partners," said James G. Carlson, AMERIGROUP Chairman and Chief Executive Officer. "Our responsibility to our shareholders, associates, members, providers and government partners is to close this chapter now and move toward the future."

The Company will report a one-time charge for the settlement of approximately $199 million net of the estimated tax benefit, in the second quarter ended June 30, 2008. The Company will pay the settlement from restricted funds previously established to cover costs related to the judgment. Following the payment, which is expected to occur during the third quarter of 2008, the Company's unrestricted cash balance will increase by approximately $117 million due to the release of excess restricted funds. These funds will be available for general corporate purposes. The Company will also be favorably impacted by estimated tax benefits of approximately $35 million.

The Company will provide full-year 2008 earnings guidance in its previously scheduled second quarter earnings release on Wednesday, July 23, 2008.

Unrelated to this case, AMERIGROUP Illinois voluntarily ended its contract with Illinois in 2006 and no longer operates in that State. The Company also has expanded its corporate compliance program significantly to fully ensure compliance with state and federal regulations in its health plans.

About AMERIGROUP Corporation

AMERIGROUP Corporation, headquartered in Virginia Beach, Virginia, improves healthcare access and quality for the financially vulnerable, seniors and people with disabilities by developing innovative managed health services for the public sector. Through its subsidiaries, AMERIGROUP Corporation serves approximately 1.7 million people in Florida, Georgia, Maryland, New Jersey, New Mexico, New York, Ohio, South Carolina, Tennessee, Texas and Virginia. For more information, visit

Forward-Looking Statements

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the Securities and Exchange Commission's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements related to the proposed settlement of the qui tam litigation and the terms of such settlement, if any, which are subject to numerous factors, many of which are outside of our control. These statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. We can give no assurances that any forward-looking statements, including statements regarding the completion of the definitive settlement documentation, the terms of any final settlement, expected unrestricted cash balances or the tax deductibility of the settlement payments, will, in fact, transpire, and, therefore, caution investors not to place undue reliance on them. We specifically disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


Investors: Julie Loftus Trudell

Senior Vice President, Investor Relations

AMERIGROUP Corporation

(757) 321-3597

News Media: Kent Jenkins Jr.

Senior Vice President, External Communications

AMERIGROUP Corporation

(757) 769-7859

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMERIGROUP Corporation to Present at the CIBC World Markets 18th Annual Healthcare Conference on November 5
2. Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit
3. Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
4. PAREXEL Reaches Agreement To Acquire ClinPhone
5. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
6. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
7. Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
8. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
9. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
10. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
11. Fralex reaches 100th patient milestone in fibromyalgia study
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
Breaking Biology Technology:
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):